NIH’s detailed remdesivir data show ventilated COVID-19 patients unlikely to benefit

Three weeks after FDA issued Emergency Use Authorization for Gilead’s remdesivir to treat severe COVID-19, detailed preliminary data that informed the decision support the antiviral’s use but also show the drug isn’t likely to benefit the sickest patients.

Data reported Friday in The New England Journal of Medicine reiterated that the Gilead Sciences Inc. (NASDAQ:GILD) antiviral met the primary endpoint in NIH’s Phase III ACTT study to treat severe COVID-19, leading to an 11-day recovery time vs. 15 days for placebo (p<0.001). ...